亚虹医药：拟使用不超12.00亿元闲置募集资金进行现金管理

Core Viewpoint - The company, Yahuang Pharmaceutical, has announced the approval of a proposal to use up to 1.2 billion yuan of temporarily idle raised funds for cash management, focusing on safe and liquid investment products [1] Group 1: Financial Management - The board of directors approved the use of idle funds for cash management, with a maximum limit of 1.2 billion yuan [1] - The investment products will be purchased from financial institutions that offer high safety, good liquidity, and capital protection agreements [1] - The usage period for these funds is valid for 12 months from the date of board approval, and the funds can be rolled over within the approved limit [1] Group 2: Impact on Operations - This decision will not affect the progress of the fundraising investment projects or the normal production and operation of the company [1]